Floreskul Vilius, Juma Fatema Z, Daniel Anjali B, Zamir Imran, Rawdin Andrew, Stevenson Matthew, Mughal Zulf, Padidela Raja
School of Health and Related Research, The University of Sheffield, Sheffield, United Kingdom.
Dolon Ltd, London, United Kingdom.
Front Public Health. 2020 Sep 4;8:439. doi: 10.3389/fpubh.2020.00439. eCollection 2020.
Literature on the cost of management of rickets and cost-effectiveness of vitamin D supplementation in preventing rickets is lacking. This study considered the cost-effectiveness of providing free vitamin D supplementation to pregnant women and children <4 years of age with varying degrees of skin pigmentation to prevent rickets in children. Estimates for the prevalence of rickets were calculated using all cases of rickets diagnosed in Central Manchester, UK and census data from the region. Cost of management of rickets were calculated using National Health Service, UK tariffs. The efficacy of vitamin D supplementation was based on a similar programme implemented in Birmingham. Quality of life was assessed using utility estimates derived from a systematic literature review. In this analysis the intervention was considered cost-effective if the incremental cost-effectiveness ratio (ICER) is below the National Institute for Health and Care Excellence, UK cost-effectiveness threshold of £20,000 per Quality-adjusted life year (QALY). Fifty-seven patients (26 dark, 29 medium and 2 light skin tones) were managed for rickets and associated complications over 4-years. Rickets has an estimated annual incidence of 29·75 per 100,000 children <4 years of age. In the dark skin tone population vitamin D supplementation proved to be cost saving. In a medium skin tone population and light skin tone populations the ICER was £19,295 per QALY and £404,047 per QALY, respectively. Our study demonstrates that a vitamin D supplementation to prevent rickets is cost effective in dark and medium skin tone populations.
关于佝偻病管理成本以及维生素D补充剂预防佝偻病的成本效益的文献尚属空白。本研究探讨了为不同皮肤色素沉着程度的孕妇和4岁以下儿童免费提供维生素D补充剂以预防儿童佝偻病的成本效益。佝偻病患病率的估计值是根据英国曼彻斯特市中心诊断出的所有佝偻病病例以及该地区的人口普查数据计算得出的。佝偻病的管理成本是根据英国国家医疗服务体系的收费标准计算的。维生素D补充剂的疗效基于在伯明翰实施的一项类似计划。生活质量是使用从系统文献综述中得出的效用估计值进行评估的。在本分析中,如果增量成本效益比(ICER)低于英国国家卫生与临床优化研究所设定的每质量调整生命年(QALY)20,000英镑的成本效益阈值,则认为该干预措施具有成本效益。在4年期间,共对57名患者(26名肤色深、29名肤色中等和2名肤色浅)的佝偻病及相关并发症进行了治疗。据估计,4岁以下儿童佝偻病的年发病率为每10万人29.75例。在肤色深的人群中,补充维生素D被证明具有成本节约效益。在肤色中等的人群和肤色浅的人群中,ICER分别为每QALY 19,295英镑和每QALY 404,047英镑。我们的研究表明,补充维生素D预防佝偻病在肤色深和肤色中等的人群中具有成本效益。